CLC number:
On-line Access: 2024-08-27
Received: 2023-10-17
Revision Accepted: 2024-05-08
Crosschecked: 2023-12-12
Cited: 0
Clicked: 1080
Fangfang GENG, Meifang YANG, Xuan ZHANG, Hong ZHAO, De ZHOU, Jianhua HU. Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review[J]. Journal of Zhejiang University Science B,in press.Frontiers of Information Technology & Electronic Engineering,in press.https://doi.org/10.1631/jzus.B2300232 @article{title="Typical hemophagocytic syndrome associated with cytomegalovirus infection in an immunocompetent patient: a case report and literature review", %0 Journal Article TY - JOUR
1例芦可替尼成功救治免疫功能正常患者因巨细胞病毒感染导致嗜血细胞综合征的病例报告及文献回顾1浙江大学医学院附属第一医院感染科,传染病诊治国家重点实验室,国家感染性疾病临床医学研究中心,国家传染病医学中心,感染性疾病诊治协同创新中心,中国杭州市,310003 2浙江大学医学院附属第一医院血液科,中国杭州市,310003 摘要:嗜血细胞综合征是一种罕见的因大量免疫细胞不受控制的激活和增殖以及细胞因子风暴引起的致命性疾病。尽管病毒感染是其常见病因,但由巨细胞病毒引起的嗜血细胞综合征较为少见。巨细胞病毒感染通常可在免疫功能低下或缺陷人群中引起系列疾病,而在免疫功能正常人群中多表现为无症状。本文报道了一例免疫功能正常患者感染巨细胞病毒引起嗜血细胞综合征后,经芦可替尼治疗成功好转。本文旨在强调免疫功能正常患者感染巨细胞病毒后可引起严重的嗜血细胞综合征,而及时给予芦可替尼治疗可以显著改善患者预后。同时,应进一步提高临床医师对免疫功能正常人群感染巨细胞病毒的重视,并为临床工作者提供新的诊疗思路。 关键词组: Darkslateblue:Affiliate; Royal Blue:Author; Turquoise:Article
Reference[1]ChenYH, LeeCH, PeiSN, 2015. Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis. Leuk Lymphoma, 56(5):1528-1529. ![]() [2]DasR, GuanP, SpragueL, et al., 2016. Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 127(13):1666-1675. ![]() [3]DiovertiMV, RazonableRR, 2016. Cytomegalovirus. Microbiol Spectr, 4:4. ![]() [4]GaoZR, LingXY, ShiCY, et al., 2022. Tumor immune checkpoints and their associated inhibitors. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 23(10):823-843. ![]() [5]HarrisonC, KiladjianJJ, Al-AliHK, et al., 2012. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med, 366(9):787-798. ![]() [6]HeK, XuSS, ShenLJ, et al., 2022. Ruxolitinib as adjunctive therapy for hemophagocytic lymphohistiocytosis after liver transplantation: a case report and literature review. J Clin Med, 11(21):6308. ![]() [7]HeineA, HeldSA, DaeckeSN, et al., 2013. The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo. Blood, 122(7):1192-1202. ![]() [8]KeenanC, NicholsKE, AlbeituniS, 2021. Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol, 12:614704. ![]() [9]MengGQ, WangJS, WangYN, et al., 2021. Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment. Infect Dis Now, 51(3):311-313. ![]() [10]Parampalli YajnanarayanaS, StübigT, CornezI, et al., 2015. JAK1/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol, 169(6):824-833. ![]() [11]RafailidisPI, MourtzoukouEG, VarbobitisIC, et al., 2008. Severe cytomegalovirus infection in apparently immunocompetent patients: a systematic review. Virol J, 5:47. ![]() [12]RisitanoAM, Peffault de LatourR, 2020. Ruxolitinib for steroid-resistant acute GVHD. Blood, 135(20):1721-1722. ![]() [13]SepulvedaFE, de Saint BasileG, 2017. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol, 49:20-26. ![]() [14]ShenCH, HwangCE, ChenYY, et al., 2014. Hepatitis B virus reactivation associated with ruxolitinib. Ann Hematol, 93(6):1075-1076. ![]() [15]SridharS, ChungTWH, ChanJFW, et al., 2018. Emergence of cytomegalovirus mononucleosis syndrome among young adults in Hong Kong linked to falling seroprevalence: results of a 14-year seroepidemiological study. Open Forum Infect Dis, 5(10):ofy262. ![]() [16]TongLX, JacksonJ, KerstetterJ, et al., 2014. Reactivation of herpes simplex virus infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol, 70(3):e59-e60. ![]() [17]VannucchiAM, 2015. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med, 372(17):1670-1671. ![]() [18]WangX, DaiCY, YinYF, et al., 2021. Blocking the JAK2/STAT3 and ERK pathways suppresses the proliferation of gastrointestinal cancers by inducing apoptosis. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 22(6):492-503. ![]() Journal of Zhejiang University-SCIENCE, 38 Zheda Road, Hangzhou
310027, China
Tel: +86-571-87952783; E-mail: cjzhang@zju.edu.cn Copyright © 2000 - 2025 Journal of Zhejiang University-SCIENCE |
Open peer comments: Debate/Discuss/Question/Opinion
<1>